Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark D Rothmann

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Lifetime Data Analysis|September 8, 2006
Inferences on a life distribution by sampling from the ages or the ages at deathMark D Rothmann
Journal of Biopharmaceutical Statistics|August 19, 2003
On non-inferiority analysis based on delta-method confidence intervalsMark D Rothmann, Hsiao-Hui Tsou
Clinical Trials (London, England)|April 25, 2023
Finding the (biomarker-defined) subgroup of patients who benefit from a novel therapy: No time for a game of hide and seekLisa Meier McShane, Mark D Rothmann, Thomas R Fleming
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2009
Issues in using progression-free survival when evaluating oncology productsThomas R Fleming, Mark D Rothmann, Hong Laura Lu
Drug Information Journal|June 23, 2012
Testing in a Prespecified Subgroup and the Intent-to-Treat PopulationMark D Rothmann, Jenny J Zhang, Laura Lu, et al.
Clinical Trials (London, England)|August 13, 2011
Some essential considerations in the design and conduct of non-inferiority trialsThomas R Fleming, Katherine Odem-Davis, Mark D Rothmann, et al.
Journal of Biopharmaceutical Statistics|February 26, 2010
Missing data in biologic oncology productsMark D Rothmann, Kallappa Koti, Kyung Yul Lee, et al.
Statistics in Medicine|May 21, 2025
A Perspective on the Appropriate Implementation of ICH E9(R1) Addendum Strategies for Handling Intercurrent EventsThomas R Fleming, Kevin J Carroll, Janet T Wittes, et al.
Statistics in Medicine|June 24, 2026
Rejoinder to Commentaries on "A Perspective on the Appropriate Implementation of ICH E9(R1) Addendum Strategies for Handling Intercurrent Events"Thomas R Fleming, Kevin J Carroll, Janet T Wittes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2008
Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancerVinni Juneja, Patricia Keegan, Joseph E Gootenberg, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Lifetime Data Analysis|September 8, 2006
Inferences on a life distribution by sampling from the ages or the ages at deathMark D Rothmann
Journal of Biopharmaceutical Statistics|August 19, 2003
On non-inferiority analysis based on delta-method confidence intervalsMark D Rothmann, Hsiao-Hui Tsou
Clinical Trials (London, England)|April 25, 2023
Finding the (biomarker-defined) subgroup of patients who benefit from a novel therapy: No time for a game of hide and seekLisa Meier McShane, Mark D Rothmann, Thomas R Fleming
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2009
Issues in using progression-free survival when evaluating oncology productsThomas R Fleming, Mark D Rothmann, Hong Laura Lu
Drug Information Journal|June 23, 2012
Testing in a Prespecified Subgroup and the Intent-to-Treat PopulationMark D Rothmann, Jenny J Zhang, Laura Lu, et al.
Clinical Trials (London, England)|August 13, 2011
Some essential considerations in the design and conduct of non-inferiority trialsThomas R Fleming, Katherine Odem-Davis, Mark D Rothmann, et al.
Journal of Biopharmaceutical Statistics|February 26, 2010
Missing data in biologic oncology productsMark D Rothmann, Kallappa Koti, Kyung Yul Lee, et al.
Statistics in Medicine|May 21, 2025
A Perspective on the Appropriate Implementation of ICH E9(R1) Addendum Strategies for Handling Intercurrent EventsThomas R Fleming, Kevin J Carroll, Janet T Wittes, et al.
Statistics in Medicine|June 24, 2026
Rejoinder to Commentaries on "A Perspective on the Appropriate Implementation of ICH E9(R1) Addendum Strategies for Handling Intercurrent Events"Thomas R Fleming, Kevin J Carroll, Janet T Wittes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2008
Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancerVinni Juneja, Patricia Keegan, Joseph E Gootenberg, et al.
Pageof 2